61 related articles for article (PubMed ID: 16253502)
1. Fludarabine phosphate-CVP in patients over 60 years of age with advanced, low-grade and follicular lymphoma: a dose-finding study.
Soubeyran P; Monnereau A; Eghbali H; Soubeyran I; Kind M; Cany L; Buy E; Guibon O; Hoerni B
Eur J Cancer; 2005 Nov; 41(17):2630-6. PubMed ID: 16253502
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib ADDED to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: a phase II study by the National Cancer Institute of Canada Clinical Trials Group.
Sehn LH; MacDonald D; Rubin S; Cantin G; Rubinger M; Lemieux B; Basi S; Imrie K; Gascoyne RD; Sussman J; Chen BE; Djurfeldt M; Shepherd L; Couban S; Crump M
J Clin Oncol; 2011 Sep; 29(25):3396-401. PubMed ID: 21810681
[TBL] [Abstract][Full Text] [Related]
3. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant Non-Hodgkin's lymphoma.
Hagenbeek A; Eghbali H; Monfardini S; Vitolo U; Hoskin PJ; de Wolf-Peeters C; MacLennan K; Staab-Renner E; Kalmus J; Schott A; Teodorovic I; Negrouk A; van Glabbeke M; Marcus R
J Clin Oncol; 2006 Apr; 24(10):1590-6. PubMed ID: 16575010
[TBL] [Abstract][Full Text] [Related]
4. Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen.
Klasa RJ; Meyer RM; Shustik C; Sawka CA; Smith A; Guévin R; Maksymiuk A; Rubinger M; Samosh M; Laplante S; Grenier JF
J Clin Oncol; 2002 Dec; 20(24):4649-54. PubMed ID: 12488409
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for low-grade follicular lymphomas.
Rohatgi N; LaRocca RV; Bard V; Sethuraman G; Foon KA
Am J Hematol; 2002 Jul; 70(3):181-5. PubMed ID: 12111762
[TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study.
Link BK; Martin P; Kaminski MS; Goldsmith SJ; Coleman M; Leonard JP
J Clin Oncol; 2010 Jun; 28(18):3035-41. PubMed ID: 20458031
[TBL] [Abstract][Full Text] [Related]
7. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.
Hainsworth JD; Litchy S; Morrissey LH; Andrews MB; Grimaldi M; McCarty M; Greco FA
J Clin Oncol; 2005 Mar; 23(7):1500-6. PubMed ID: 15632411
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study.
Nowakowski GS; LaPlant B; Habermann TM; Rivera CE; Macon WR; Inwards DJ; Micallef IN; Johnston PB; Porrata LF; Ansell SM; Klebig RR; Reeder CB; Witzig TE
Leukemia; 2011 Dec; 25(12):1877-81. PubMed ID: 21720383
[TBL] [Abstract][Full Text] [Related]
9. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Hutchison-Rzepka A; Tighiouart M; Heffner LT; Lechowicz MJ; Lonial S; Flowers CR
Cancer; 2012 Jul; 118(14):3538-48. PubMed ID: 22535574
[TBL] [Abstract][Full Text] [Related]
10. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.
Marcus R; Imrie K; Solal-Celigny P; Catalano JV; Dmoszynska A; Raposo JC; Offner FC; Gomez-Codina J; Belch A; Cunningham D; Wassner-Fritsch E; Stein G
J Clin Oncol; 2008 Oct; 26(28):4579-86. PubMed ID: 18662969
[TBL] [Abstract][Full Text] [Related]
11. Favorable impact of low-dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non-Hodgkin's lymphomas.
Bocchia M; Bigazzi C; Marconcini S; Forconi F; Marotta G; Algeri R; Lauria F
Haematologica; 1999 Aug; 84(8):716-20. PubMed ID: 10457407
[TBL] [Abstract][Full Text] [Related]
12. Fludarabine and cyclophosphamide using an attenuated dose schedule is a highly effective regimen for patients with indolent lymphoid malignancies.
Tam CS; Wolf MM; Januszewicz EH; Prince HM; Westerman D; Seymour JF
Cancer; 2004 May; 100(10):2181-9. PubMed ID: 15139062
[TBL] [Abstract][Full Text] [Related]
13. Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma.
Luminari S; Marcheselli L; Sacchi S; Pozzi S; Bari A; Ilariucci F; Stelitano C; Angrilli F; Lazzaro A; Baldini L
Cancer; 2009 May; 115(9):1906-13. PubMed ID: 19248044
[TBL] [Abstract][Full Text] [Related]
14. Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.
Sacchi S; Pozzi S; Marcheselli R; Federico M; Tucci A; Merli F; Orsucci L; Liberati M; Vallisa D; Brugiatelli M;
Cancer; 2007 Jul; 110(1):121-8. PubMed ID: 17503433
[TBL] [Abstract][Full Text] [Related]
15. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
16. Prolonged disease-free survival and overall survival with CVP alternating with fludarabine in advanced follicular lymphoma.
Ai WZ; Kohrt HE; Timmerman J; Hwang J; Hsu FJ; Czerwinski DD; Taidi B; Levy R
Am J Hematol; 2011 Jun; 86(6):515-8. PubMed ID: 21538469
[No Abstract] [Full Text] [Related]
17. Immunochemotherapy with rituximab, vincristine and 5-day cyclophosphamide for heavily pretreated follicular lymphoma.
Lazzarino M; Arcaini L; Orlandi E; Iacona I; Bernasconi P; Calatroni S; Varettoni M; Isa L; Brusamolino E; Bonfichi M; Passamonti F; Burcheri S; Pascutto C; Regazzi M
Oncology; 2005; 68(2-3):146-53. PubMed ID: 16006752
[TBL] [Abstract][Full Text] [Related]
18. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.
Zinzani PL; Pulsoni A; Perrotti A; Soverini S; Zaja F; De Renzo A; Storti S; Lauta VM; Guardigni L; Gentilini P; Tucci A; Molinari AL; Gobbi M; Falini B; Fattori PP; Ciccone F; Alinari L; Martelli M; Pileri S; Tura S; Baccarani M
J Clin Oncol; 2004 Jul; 22(13):2654-61. PubMed ID: 15159414
[TBL] [Abstract][Full Text] [Related]
19. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.
Czuczman MS; Weaver R; Alkuzweny B; Berlfein J; Grillo-López AJ
J Clin Oncol; 2004 Dec; 22(23):4711-6. PubMed ID: 15483015
[TBL] [Abstract][Full Text] [Related]
20. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphoma.
Meyer RM; Quirt IC; Skillings JR; Cripps MC; Bramwell VH; Weinerman BH; Gospodarowicz MK; Burns BF; Sargeant AM; Shepherd LE
N Engl J Med; 1993 Dec; 329(24):1770-6. PubMed ID: 7694148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
